

Thurse	day, 09 November 2023 09	9:00 - 18:40
09:00	Welcome and Introduction	Falk Klar,
		PDA Europe
09:05	Welcome Remarks from Workshop Co-Chairs	Frederic B. Ayers,
		ValSource
		Tracy Moore, TM
00.20	D1. Oversieve of and Davisian Ducases for EU CMD Assess 1	Pharma Group
09:20 – 10:40	P1: Overview of and Revision Process for EU GMP Annex 1 Over the past four years, the revised EU GMP Annex 1 has gone through	Moderator: Frederic B. Ayers,
10.40	multiple sets of industry reviews, comments, and revisions. The current	ValSource
	version presents a diverse, international perspective on regulatory	Valsource
	expectations, recommendations, and requirements for modern sterile drug	
	and biologic product manufacturing. The revised EU GMP Annex 1	
	contains a significant amount of new and more detailed content on many	
	topics. It places a heightened emphasis on the use of risk-based	
	assessment and approaches to design and evaluate manufacturing	
	contamination control. This session will provide insights from regulatory	
	authorities involved in the EU GMP Annex 1 development and review	
	process of the revision, with a focus on the evolution, planning, and	
00.20	implementation of these changes.	Dussautau
09:20	Update to the Annex 1 Guideline on Manufacture of Sterile Products	Presenter: Roberto Conocchia,
		EMA
		(remote
		presentation)
09:45	U.S. FDA Regulatory Perspective on Sterile Manufacturing and Current	Presenter:
	Trends in Biologics Inspection Findings	Derek Smith,
		U.S. FDA
10:10	Q&A and Panel Discussion	
10:40	Coffee Break, Poster & Exhibition	
11:10 -	P2: Scope, Principles, and Pharmaceutical Quality Systems	Moderator:
12:25	This session opens our in-depth look at the content of the draft EU GMP	Derek Duncan,
	Annex 1. The Scope, Principles, and Pharmaceutical Quality System	LIGHTHOUSE
	sections introduce the vision of the EU GMP Annex 1 changes that track through all other sections. Talks will highlight EU GMP Annex 1 focal	Instruments
	points including contamination control strategy, quality risk management,	
	and quality culture, including a discussion on the importance of human	
	factors: knowledge, attitude, and experience. This session will also address	
	the expanded scope of EU GMP Annex 1 to include some non-sterile drug	
	products.	
11:10	Using Quality Risk Management to Enable the Contamination Control	Presenter:
	Strategy	



		Amanda M.
		McFarland,
		ValSource
11:30	Contract Manufacturing Organizations	Presenter:
		Speaker Invited
11:50	Considerations on implications of EU & PIC/S GMP Annex 1 for Advanced	Presenter:
	Therapy Medicinal Products and Low Bioburden Products	Francesco Cicirello,
		BioNTech
12:10		(remotely)
12:10	Q&A, Discussion	
12:25	Transition to Breakout Session	
12:30	Breakout Session 1	
	Attendees will discuss the implementation challenges, and what can be	
	done to meet those challenges, associated with the topics presented in	
	P1: Overview of and Revision Process for EU GMP Annex 1 and P2: Scope, Principles, and Pharmaceutical Quality Systems.	
13:10	Lunch Break, Poster & Exhibition	
14:10 -	P3: Premises and Barrier Systems	Moderator:
14.10 -	Aseptic manufacturing facilities come in a variety of shapes and sizes,	Patrizia Muscas,
13.23	from traditional aseptic through restricted access barrier systems (RABS)	Eli Lilly and
	and Isolators. This session will look at some of the key design and	Company
	operational aspects that have been impacted by the revised EU GMP	company
	Annex 1.	
14:10	Cleanroom Design: Classification, Qualification, Air Visualization	Presenter:
		Frederic B. Ayers,
		ValSource
14:30	Cleanroom Operation: Disinfection, Transfer of Materials, Monitoring	Presenter:
		David Keen,
		Ecolab
14:50	Barrier Technologies: RABS and Isolators, Glove Integrity, Robotics	Presenter:
	Decontamination	Richard Denk,
		SKAN
45.40		
15:10	Q&A, Discussion	Moderator:
15:25	Transition to Breakout Session	
15:30	Breakout Session 2	
	Attendees will discuss the implementation challenges, and what can be	
	done to meet those challenges, associated with the topics presented in	
16:10	P3: Premises and Barrier Systems. Coffee Break, Poster & Exhibition	
16:40 -	P4: Equipment, Technology, and Utilities	Moderator:
16:40 -	ra. Equipment, recimology, and othiles	David Keen, Ecolab
17.55		Daviu Reell, ECOIUD



	This session will discuss the impact of the EU GMP Annex 1 revision on aseptic manufacturing facilities, specifically focusing on equipment design, indirect product contact parts, such as stopper bowls, and critical utilities, such as water systems.	
16:40	Material Transfer	Presenter:
		Tracy Moore <i>, TM</i> Pharma Group
17:00	Decontamination and Sterilization of Direct and Indirect Product Contact Surfaces	Presenter: Richard Denk, SKAN
17:20	Aseptic Process Simulations	Presenter: Patrizia Muscas, Eli Lilly and Company
17:40	Q&A, Discussion	
17:55	Transition to Breakout Session	
18:00	Breakout Session 3 Attendees will discuss the implementation challenges, and what can be done to meet those challenges, associated with the topics presented in P4: Equipment, Technology, and Utilities.	
18:40 - 20:10	End of Workshop Day 1 & Networking Reception	

Friday,	, 10 November 2023 0	8:00 - 17:00
08:00	Welcome and Day 1 Report Out	Moderator:
		Tracy Moore, TM Pharma Group
08:20 – 09:15	P5: Personnel Training, Qualification, Gowning, and Monitoring/Assessment Training and qualifying operators are of critical importance to ensuring proper aseptic technique and cleanroom behavior. Routine monitoring of personnel ensures that the qualified personnel are following the established procedures and that they can meet the strict gowning cleanliness requirements during normal operations. Trending and analysis of gloves and gown environmental monitoring (EM) data can provide	Moderator: Tracy Moore, TM Pharma Group
	critical feedback on individual operator performance, potential routes of contamination, specific gowning procedures, and overall training efficacy.	
08:20	Qualification and Training	Presenter: Patrick Nieuwenhuizen, PharmaLex
08:40	Gowning, Personnel Monitoring, and Beyond	Presenter: Frederic B. Ayers, <i>ValSource</i>



09:00	Q&A, Discussion	
09:15	Transition to Breakout Sessions	
09:20	Breakout Session 4	
05.20	Attendees will discuss the implementation challenges, and what can be	
	done to meet those challenges, associated with the topics presented in	
	P5: Personnel Training, Qualification, Gowning, and	
	Monitoring/Assessment.	
10:00	Coffee Break, Poster Sessions & Exhibition	
10:30 -		Moderator:
10:30 -	P6: Production Technologies, Part 1 <i>This session will focus on the EU GMP Annex 1 requirements for aseptic</i>	David Keen, Ecolab
11.25	processing and filtration of sterile products. The aseptic processing	David Reell, Ecolub
	discussion will address the types of operations and grades needed for	
	aseptic preparation and processing operations. The filtration and	
	sterilization presentation will provide insight into the different types of	
10:30	sterilization and the parameters needed to demonstrate success.	Drocontor:
10:30	Aseptic Processing	Presenter:
		Frederic B. Ayers,
10.50	Filmation and Dup was Dept Chaviliantian Internity Testing	ValSource
10:50	Filtration and Pre-use Post Sterilization Integrity Testing	Presenter:
44.40		Thao Vin Le, GSK
11:10	Q&A, Discussion	
11:25	Transition to Breakout Sessions	
11:30	Breakout Session 5	
	Attendees will discuss the implementation challenges, and what can be	
	done to meet those challenges, associated with the topics presented in	
	P6: Production Technologies, Part 1 (Aseptic Processing and Filtration and	
	Pre-Use Post Sterilization Integrity Testing).	
12:10	Lunch Break, Poster & Exhibition	
13:10 -	P7: Production Technologies, Part 2	Moderator:
14:05	This session will introduce some of the more intriguing topics covered and	Amanda M.
	expanded in the revised EU GMP Annex 1, which were selected based on	McFarland,
	input from the sterile product manufacturing community, as noted during	ValSource
	prior meetings and discussions.	
13:10	Container Closure Integrity Testing and Finishing	Presenter:
		Derek Duncan,
		Lighthouse
		Instruments
13:30	Production and Specific Technologies (Blow-Fill-Seal, Lyophilization, Single	Presenter:
	Use System, and Terminal Sterilization)	Patrick
		Nieuwenhuizen,
		PharmaLex
13:50	Q&A, Discussion	
14:05	Transition to Breakout Sessions	
14:10	Breakout Session 6	
	Attendees will discuss the implementation challenges, and what can be	
	done to meet those challenges, associated with the topics presented in	



17:00	End of Workshop	
16:55	Closing Remarks & Farewell	Falk Klar, PDA Europe
16:40	Day 2 Report Out & Closing Remarks from Workshop Co-Chairs	Frederic B. Ayers, ValSource Tracy Moore, TM Pharma Group
16:00	Q&A & Final Panel Discussion Join our Discussion with Experts from the Industry and Regulatory: Frederic B. Ayers, ValSource Francesco Cicirello, BioNTech Kurt Jaecques, GSK Amanda M. McFarland, ValSource Tracy Moore, TM Pharma Group Derek Smith, U.S. FDA	Moderator: Richard Denk, SKAN
15:40	Contamination Control Strategy Development	Presenter: Amanda M. McFarland, ValSource
15:20	Environmental and Process Monitoring	Presenter: Kurt Jaecques, <i>GSK</i>
<mark>14:50</mark> 15:20 – 17:00	 P7: Production Technologies, Part 2 (Container Closure Integrity Testing and Finishing and Production and Specific Technologies (Blow-Fill-Seal, Lyophilization, Single Use System, and Terminal Sterilization). Coffee Break, Poster & Exhibition P8: Environmental Monitoring and Contamination Control Strategy Aseptic Process Simulation (APS) has been identified as one of the key aspects of aseptic process control and monitoring. This session will review the related changes and begin discussing the interpretation and implementation of these recommendations and requirements. The presentations will focus on the EU GMP Annex 1 requirements for APS (media fills) and environmental and process monitoring, including the new requirements and considerations for qualifying and operating a clean area and the extensive new requirements needed to successfully validate an aseptic process. 	Moderator: Richard Denk, SKAN

The agenda is subject to change without notice, Speakers are invited pending confirmation.